Active Motif Partners with Arima Genomics to Enhance 3D Genomic Solutions
Active Motif, a leading provider of epigenetic and multi-omic solutions for mechanistic biology research, has announced an exclusive global distribution agreement with Arima Genomics, a company specializing in cancer diagnostics. This strategic partnership aims to leverage Arima's cutting-edge 3D genomic technology and Hi-C sequencing solutions to enhance Active Motif's research portfolio, particularly in the realms of mechanistic, translational, and clinical biology.
The significance of this collaboration is underscored by the increasing demand for technologies that allow researchers to comprehend how genome structure influences gene regulation, cellular function, and disease biology. With Arima’s expertise, Active Motif is set to become the exclusive global distributor for Arima’s Hi-C products and services tailored for research purposes, while Arima will focus on advancing its Aventa clinical diagnostic platform.
Joe Fernandez, the chairman and founder of Active Motif, highlighted the need for comprehensive insights into genomic operations. He expressed that as researchers increasingly seek holistic views that integrate chromatin accessibility, transcription factor binding, epigenetic regulation, gene expression, and genomic architecture, incorporating technology like Hi-C broadens the answers to pivotal questions in modern biology.
The deal represents a crucial step for Active Motif, further solidifying its position as a premier provider of integrated multi-omic solutions. The collaboration enhances Active Motif's continually expanding portfolio, which already features services and products for chromatin profiling, transcriptional regulation, and next-generation sequencing applications.
As genomic research evolves past sequence-based analyses, 3D genomic mapping technologies such as Hi-C have become invaluable for understanding chromatin organization, structural variations, and the interplay between enhancers and promoters. Such insights hold increasing relevance in fields including cancer research, neuroscience, developmental biology, rare disease investigations, and precision medicine.
Arima Genomics focuses on the promising prospects for its Aventa clinical diagnostic platform, which combines sequencing and structural analysis of DNA to detect cancer-related alterations from routine FFPE tumor samples. Tom Willis, Ph.D., CEO of Arima, noted that this partnership aligns its Hi-C research technologies with Active Motif's complementary offerings, global commercial infrastructure, scientific expertise, and established relationships in the scientific community.
Effective immediately, the Hi-C products and services developed by Arima for research are now accessible worldwide through Active Motif. This agreement represents a merger of Arima's technological leadership in 3D genomic solutions with Active Motif's well-established commercial network and technical support capabilities, facilitating broader access for academic, pharmaceutical, biotechnological, and clinical research institutions.
Active Motif is recognized as a key player in providing epigenetic and genomic solutions that empower researchers to investigate gene regulation, chromatin biology, and pathophysiological mechanisms. Through innovative products and services coupled with scientific expertise, Active Motif aids researchers globally in advancing discoveries that contribute to improved human health.
Arima Genomics specializes in cancer diagnostics, revolutionizing screening tests by integrating the sequential and structural analysis of DNA. With its forefront expertise in 3D genomic science and Hi-C sequencing technology, Arima develops clinical tests aimed at identifying alterations that traditional methods may not adequately capture or characterize. Through its Aventa brand of clinical tests, Arima offers analysis for solid tumors and lymphomas from its CLIA-certified lab in Orlando, Florida. To learn more, visit www.arimagenomics.com and aventatest.com, and follow them on LinkedIn.
The significance of this collaboration is underscored by the increasing demand for technologies that allow researchers to comprehend how genome structure influences gene regulation, cellular function, and disease biology. With Arima’s expertise, Active Motif is set to become the exclusive global distributor for Arima’s Hi-C products and services tailored for research purposes, while Arima will focus on advancing its Aventa clinical diagnostic platform.
Joe Fernandez, the chairman and founder of Active Motif, highlighted the need for comprehensive insights into genomic operations. He expressed that as researchers increasingly seek holistic views that integrate chromatin accessibility, transcription factor binding, epigenetic regulation, gene expression, and genomic architecture, incorporating technology like Hi-C broadens the answers to pivotal questions in modern biology.
The deal represents a crucial step for Active Motif, further solidifying its position as a premier provider of integrated multi-omic solutions. The collaboration enhances Active Motif's continually expanding portfolio, which already features services and products for chromatin profiling, transcriptional regulation, and next-generation sequencing applications.
As genomic research evolves past sequence-based analyses, 3D genomic mapping technologies such as Hi-C have become invaluable for understanding chromatin organization, structural variations, and the interplay between enhancers and promoters. Such insights hold increasing relevance in fields including cancer research, neuroscience, developmental biology, rare disease investigations, and precision medicine.
Arima Genomics focuses on the promising prospects for its Aventa clinical diagnostic platform, which combines sequencing and structural analysis of DNA to detect cancer-related alterations from routine FFPE tumor samples. Tom Willis, Ph.D., CEO of Arima, noted that this partnership aligns its Hi-C research technologies with Active Motif's complementary offerings, global commercial infrastructure, scientific expertise, and established relationships in the scientific community.
Effective immediately, the Hi-C products and services developed by Arima for research are now accessible worldwide through Active Motif. This agreement represents a merger of Arima's technological leadership in 3D genomic solutions with Active Motif's well-established commercial network and technical support capabilities, facilitating broader access for academic, pharmaceutical, biotechnological, and clinical research institutions.
Active Motif is recognized as a key player in providing epigenetic and genomic solutions that empower researchers to investigate gene regulation, chromatin biology, and pathophysiological mechanisms. Through innovative products and services coupled with scientific expertise, Active Motif aids researchers globally in advancing discoveries that contribute to improved human health.
Arima Genomics specializes in cancer diagnostics, revolutionizing screening tests by integrating the sequential and structural analysis of DNA. With its forefront expertise in 3D genomic science and Hi-C sequencing technology, Arima develops clinical tests aimed at identifying alterations that traditional methods may not adequately capture or characterize. Through its Aventa brand of clinical tests, Arima offers analysis for solid tumors and lymphomas from its CLIA-certified lab in Orlando, Florida. To learn more, visit www.arimagenomics.com and aventatest.com, and follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.